✨ Free AI Report
ASLAN Pharmaceuticals Ltd: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ASLAN Pharmaceuticals Ltd
Company Research

ASLAN Pharmaceuticals Ltd: Business Overview, Financials & Competitive Analysis

ASLAN Pharmaceuticals Ltd scores 3/10 on the AskCyborg Cyborg Score (Challenged). Biotech pipeline at risk due to regulatory delisting and capital constraints; viability dependent on clinical trial success and alternative funding sources. The company was delisted from Nasdaq in July 2024 due to non-compliance with bid price and stockholders' equity requirements, and the company's board determined not to appeal the.

What is ASLAN Pharmaceuticals Ltd's industry? ASLAN Pharmaceuticals Ltd (aslanpharma.com) operates in Immunology Drugs. AskCyborg classifies ASLAN Pharmaceuticals Ltd under Immunology Drugs in its company registry.

ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is developing eblasakimab, a potential first-in-c...

3/ 10Challenged

Cyborg Score thesis

Biotech pipeline at risk due to regulatory delisting and capital constraints; viability dependent on clinical trial success and...

Read the full analyst-debate transcript →
Industry Immunology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest ASLAN Pharmaceuticals Ltd Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for ASLAN Pharmaceuticals Ltd

AskCyborg analysts argue the bull and bear cases for ASLAN Pharmaceuticals Ltd across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ASLAN Pharmaceuticals Ltd OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

ASLAN Pharmaceuticals Ltd Overview

Pro stress-test →

ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study.

Strategic Profile

Pro stress-test →

ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, the company is headquartered in Singapore and has offices in Taiwan and China.

Competitive Landscape

Pro stress-test →

In atopic dermatitis, ASLAN competes with established biologics including Dupilumab (Sanofi/Regeneron) and Tralokinumab (Eli Lilly). The IL-13 receptor targeting approach differentiates eblasakimab from current therapies. In alopecia areata, early-stage competitors include JAK inhibitors and other immune modulators under development.

Industry Context

ASLAN Pharmaceuticals Ltd operates in Immunology Drugs.

Key facts

Founded: 2009 · Headquarters: Singapore, Singapore · Employees: 44 · Revenue: $9.1M

What the analysts stress-tested

The top findings that survived the multi-agent debate for ASLAN Pharmaceuticals Ltd.

  • Delisted from NASDAQ (July 2024) due to failure to meet listing standards; now trades over-the-counter
  • Lead candidate eblasakimab showed positive Phase 2b data in atopic dermatitis; Phase 2 trial (TREK-DX) ongoing
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2024Delisted from Nasdaq after failing to meet $1.00 bid price and $2.5M stockholders' equity requirements
  • 2024Reported positive Phase 2b topline data for eblasakimab in moderate-to-severe atopic dermatitis
  • +1 moreTrack every material event for ASLAN Pharmaceuticals Ltd as it happens. Explore monitoring →
Get alerted when ASLAN Pharmaceuticals Ltd has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupilumabIL-4 receptor antibody for atopic dermatitis and other allergic conditions→TralokinumabIL-13 antibody for atopic dermatitis→JAK InhibitorsOral immunosuppressants for alopecia areata and dermatologic conditions→

Compare ASLAN Pharmaceuticals Ltd with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ASLAN Pharmaceuticals Ltd operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about ASLAN Pharmaceuticals Ltd

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ASLAN Pharmaceuticals Ltd and its top competitor on Cyborg Score”
“What did ASLAN Pharmaceuticals Ltd do this quarter?”
“Is ASLAN Pharmaceuticals Ltd a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does ASLAN Pharmaceuticals Ltd do?+
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is developing eblasakimab, a potential first-in-c...
What is ASLAN Pharmaceuticals Ltd's Cyborg Score?+
ASLAN Pharmaceuticals Ltd has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ASLAN Pharmaceuticals Ltd's main competitors?+
Named competitors include Dupilumab, Tralokinumab, JAK Inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full ASLAN Pharmaceuticals Ltd research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ASLAN Pharmaceuticals Ltd research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ASLAN Pharmaceuticals Ltd over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.